Document is current
Any future updates will be listed below
-
Authors
Sozzi, Gabriella
Sabia, Federica
Rolli, Luigi
Segale, Miriam
Suatoni, Paola
Zanghi, Anna
Ruggirello, Margherita
Marchianò, Alfonso
Boeri, Mattia
Pastorino, Ugo
-
Funding
Funding for this research was provided by:
Fondazione AIRC per la ricerca sul cancro ETS (IG12162, IG18812 and IG23244)
Horizon 2020 (n.848294, n.848294)
National Cancer Institute (EDRN UO1-CA166905, EDRN UO1-CA166905)
Gensignia Life Science
Ministero della Salute (RF-2021-12373449, RF-2021-12373449)
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 21 May 2025
First Online: 31 May 2025
Declarations
:
: The study was approved by the Institutional Review Board and Ethics Committee and complied with the Declaration of Helsinki.
: Not applicable.
: GS, MB and UP are co-inventors of three patent applications regarding the miRNA signature classifier. These patents were licensed to a private company, Gensignia Life Science, under the regulations of Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. MB and UP declare a consulting agreement with Accustem. All other authors declare no competing interests.
